First Phase III IBD Trial Reads Out Positive For Janssen’s Tremfya
Data From More Studies Expected Later This Year
Executive Summary
The IL-23 inhibitor, entering an increasingly competitive space, posted significant results at Digestive Disease Week from the Phase IIb/III QUASAR induction study in ulcerative colitis.
You may also be interested in...
AbbVie’s Skyrizi Bests Stelara Head-To-Head In Crohn’s
Data showing superiority on endoscopic remission and non-inferiority on clinical remission could position AbbVie’s IL-23 inhibitor to move ahead of Stelara in treatment paradigm.
Lilly Strikes Out With The FDA For Second Time This Year With Mirikizumab CRL
With mirikizumab delayed until Lilly overcomes the FDA’s manufacturing concerns, the company has fallen behind on its goal of five approvals in 2023.
AbbVie’s Skyrizi Checks One Last Box With Phase III Success In Ulcerative Colitis
Already approved in Crohn’s disease, Skyrizi now has positive Phase III results in ulcerative colitis with more data expected this year in UC as the field grows more crowded with anti-IL-23 options.